UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?

Cell cycle (Georgetown, Tex.), 2009-10, Vol.8 (20), p.3291-3296

Michieli, Paolo

2009

Volltextzugriff (PDF)

Microscope-Based Automated Quantification of Liver Fibrosis in Mice Using a Deep Learning Algorithm

Toxicologic pathology, 2021-07, Vol.49 (5), p.1126-1133

2021

Volltextzugriff (PDF)

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Cancer cell, 2003-04, Vol.3 (4), p.347-361

2003

Volltextzugriff (PDF)

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs

Cancer research (Chicago, Ill.), 2014-11, Vol.74 (22), p.6598-6609

2014

Volltextzugriff (PDF)

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met

The Journal of biological chemistry, 2008-07, Vol.283 (30), p.21267-21277

2008

Volltextzugriff (PDF)

A Mesenchymal‐Epithelial Transition Factor‐Agonistic Antibody Accelerates Cirrhotic Liver Regeneration and Improves Mouse Survival Following Partial Hepatectomy

Liver transplantation, 2022-05, Vol.28 (5), p.782-793

2022

Volltextzugriff (PDF)

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

Cancer cell, 2004-07, Vol.6 (1), p.61-73

2004

Volltextzugriff (PDF)

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

Cell reports (Cambridge), 2014-06, Vol.7 (6), p.1940-1955

2014

Volltextzugriff (PDF)

Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis

The Journal of clinical investigation, 2009-04, Vol.119 (4), p.865-875

2009

Volltextzugriff (PDF)

Expression and Functional Regulation of Myoglobin in Epithelial Cancers

The American journal of pathology, 2009-07, Vol.175 (1), p.201-206

2009

Volltextzugriff (PDF)

Correction: Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis

PloS one, 2019-07, Vol.14 (7), p.e0220357-e0220357

2019

Volltextzugriff (PDF)

Tivantinib—a cytotoxic drug in MET inhibitor's clothes?

Nature reviews. Clinical oncology, 2013-07, Vol.10 (7), p.372-374

2013

Volltextzugriff (PDF)

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

Nature (London), 1998-01, Vol.391 (6664), p.285-288

1998

Volltextzugriff (PDF)

Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis

PloS one, 2008-09, Vol.3 (9), p.e3223-e3223

2008

Volltextzugriff (PDF)

Abstract C116: Concomitant blockade of glucose uptake and paracrine HGF signaling uncovers the metabolic vulnerability of KRAS-mutant colorectal tumors

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C116-C116

2015

Volltextzugriff (PDF)

Abstract B37: Concomitant blockade of glucose uptake and paracrine HGF signaling uncovers the metabolic vulnerability of KRAS-mutant colorectal tumors

Molecular cancer research, 2016-01, Vol.14 (1_Supplement), p.B37-B37

2016

Volltextzugriff (PDF)

Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?

Nature reviews. Clinical oncology, 2013-07, Vol.10 (7), p.372-374

2013

Volltextzugriff (PDF)

Abstract 3726: Inhibition of MET overcomes invasive resistance to Bevacizumab and prolongs survival in orthotopic mouse models of glioblastoma multiforme

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3726-3726

2014

Volltextzugriff (PDF)

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

Clinical cancer research, 2013-05, Vol.19 (9), p.2381-2392

2013

Volltextzugriff (PDF)

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

Oncogene, 1999-09, Vol.18 (37), p.5221-5231

1999

Volltextzugriff (PDF)

Metron factor‐1 prevents liver injury without promoting tumor growth and metastasis

Hepatology (Baltimore, Md.), 2008-06, Vol.47 (6), p.2010-2025

2008

Volltextzugriff (PDF)

Uncoupling Signal Transducers from Oncogenic MET Mutants Abrogates Cell Transformation and Inhibits Invasive Growth

Proceedings of the National Academy of Sciences - PNAS, 1998-11, Vol.95 (24), p.14379-14383

1998

Volltextzugriff (PDF)

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response

Clinical cancer research, 2013-08, Vol.19 (15), p.4291-4291

2013

Volltextzugriff (PDF)

Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors

Oncotarget, 2017-06, Vol.8 (24), p.38193-38213

2017

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Englisch
(95)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(52)
Humans
(45)
Animals
(28)
Mice
(24)
Female
(19)
Oncology
(17)
Proto-Oncogene Proteins C-Met - Metabolism
(17)
Male
(14)
Biological And Medical Sciences
(12)
Cancer
(12)
Cell Biology
(12)
Biochemistry & Molecular Biology
(11)
Cell Line, Tumor
(10)
Middle Aged
(10)
Phosphorylation
(10)
Adult
(9)
Medicine, Research & Experimental
(9)
Physical Sciences
(9)
Proto-Oncogene Proteins C-Met - Genetics
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe?

Microscope-Based Automated Quantification of Liver Fibrosis in Mice Using a Deep Learning Algorithm

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met

A Mesenchymal‐Epithelial Transition Factor‐Agonistic Antibody Accelerates Cirrhotic Liver Regeneration and Improves Mouse Survival Following Partial Hepatectomy

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer

Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis

Expression and Functional Regulation of Myoglobin in Epithelial Cancers

Correction: Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis

Tivantinib—a cytotoxic drug in MET inhibitor's clothes?

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis

The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients

Abstract C116: Concomitant blockade of glucose uptake and paracrine HGF signaling uncovers the metabolic vulnerability of KRAS-mutant colorectal tumors

Abstract B37: Concomitant blockade of glucose uptake and paracrine HGF signaling uncovers the metabolic vulnerability of KRAS-mutant colorectal tumors

Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?

Abstract 3726: Inhibition of MET overcomes invasive resistance to Bevacizumab and prolongs survival in orthotopic mouse models of glioblastoma multiforme

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

Metron factor‐1 prevents liver injury without promoting tumor growth and metastasis

Uncoupling Signal Transducers from Oncogenic MET Mutants Abrogates Cell Transformation and Inhibits Invasive Growth

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response

Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors

Suchergebnisse filtern